- IN₹229.07bn
- IN₹234.65bn
- IN₹53.66bn
Brief: Granules - Unit V Facility Secures US FDA EIR With 'No Action Indicated' Status
Brief: Granules India Q2 Consol Profit 972.3 Million Rupees
Granules India Q2 profit falls on weak demand in North America, Europe
Granules India set for worst day in almost 4-1/2 yrs as investors seek clarity on FDA observations
Brief: Granules Updates On Gagillapur FD Facility
Pharma firm Granules India plunges after USFDA scrutiny
Brief: Granules Gets ANDA Approval For Glycopyrrolate Oral Solution
Granules India's Q1 profit nearly triples on strong demand
Granules India hits record high on quarterly profit rise
Brief: Granules June-Quarter Consol Net Profit 1.35 Billion Rupees
Indian pharma stocks head for best week in more than two years
Drugmaker Granules India falls after Q4 revenue slides
Granules India posts Q4 revenue fall on weak paracetamol sales, price erosion
Brief: Granules India Re-Appoints Krishna Prasad Chigurupati As Chairman, MD
Brief: Granules India Gets Tax Order For Total Amount At 2.1 Million Rupees
Brief: Granules India Gets ANDA Approval For Colchicine Capsules
India's Glenmark Life Sciences posts lower Q4 profit as Red Sea crisis hurts API business
Brief: Granules India US FDA Audit For Granules India’S Unit V Facility Results In Zero 483s
India's Laurus Labs hits near 1-1/2 year high